Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
From MaRDI portal
Publication:454783
DOI10.1155/2012/567819zbMath1263.62132OpenAlexW2020386060WikidataQ58910973 ScholiaQ58910973MaRDI QIDQ454783
Galen Cook-Wiens, Mourad Tighiouart, André Rogatko
Publication date: 10 October 2012
Published in: Journal of Probability and Statistics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1155/2012/567819
Lua error in Module:PublicationMSCList at line 37: attempt to index local 'msc_result' (a nil value).
Related Items (1)
Cites Work
- Unnamed Item
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- Dose finding in drug development.
- Continual Reassessment Method for Ordered Groups
- Bayesian Optimal Designs for Phase I Clinical Trials
- Statistical Methods for Dose‐Finding Experiments
- TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
- A Curve‐Free Method for Phase I Clinical Trials
- Bayesian Nonparametric Inference on the Dose Level with Specified Response Rate
This page was built for publication: Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control
